Pfizer Inc (PFE)

PFE (NYSE:Drugs) EQUITY
$36.91
pos +0.24
+0.65%
Today's Range: 36.65 - 36.88 | PFE Avg Daily Volume: 24,590,800
Last Update: 07/29/16 - 11:48 AM EDT
Volume: 5,682,093
YTD Performance: 13.60%
Open: $36.68
Previous Close: $36.67
52 Week Range: $28.25 - $37.19
Oustanding Shares: 6,064,849,361
Market Cap: 223,489,698,953
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 8
Moderate Buy 0 0 0 0
Hold 6 6 6 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.80 1.80 1.80 1.77
Latest Dividend: 0.30
Latest Dividend Yield: 3.26%
Dividend Ex-Date: 08/03/16
Price Earnings Ratio: 15.95
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
15.95 30.20 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
11.43% 3.73% 24.86%
GROWTH 12 Mo 3 Yr CAGR
Revenue -1.50 -0.20 -0.06
Net Income -23.80 -0.30 -0.10
EPS -21.70 -0.40 -0.17
Earnings for PFE:
EBITDA 18.13B
Revenue 48.85B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.62 $0.62 $2.45 $2.65
Number of Analysts 8 4 10 10
High Estimate $0.64 $0.66 $2.51 $2.79
Low Estimate $0.59 $0.59 $2.42 $2.36
Prior Year $0.56 $0.60 $2.20 $2.45
Growth Rate (Year over Year) 10.04% 3.33% 11.55% 8.03%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
The stock has broken free of tiresome resistance in a big way.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Let me give you the unassailable themes.
They need to do something that makes them stand out as stocks you want to own, not avoid.
A breakdown below $33 would mean sellers have gained the upper hand.
Bearish
Jun 20, 2016 | 7:11 AM EDT
PFE was removed from the Franchise Pick list, Jefferies said. Valuation call, based on a new $40 price target. 

Ardelyx Has Big Potential Real Money Pro($)

This small-cap company's shares are half where they ended 2015.
This is because they would buy more of the winning stocks lower.
These mid-caps would do well by themselves, but could tempt bigger companies.

Columnist Conversations

Thursday's Philadelphia Inquirer reported that the average requested increase for individual health insurance ...
Markets set to open slightly lower as second quarter GDP comes in at a much lower than expected 1.2% and first...
I have a new non-trade-related article published on Seeking Alpha today. http://seekingalpha.com/articl...
From Real Money's Tony Owusu: Amazon (AMZN) continued its strong run of success Thursday afternoon following...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.